Effect of reducing the dose of stavudine on body composition, bone density, and markers of mitochondrial toxicity in HIV-infected subjects: A randomized, controlled study

Clinical Infectious Diseases

Volumn 46, Issue 8, 2008, Pages 1290-1296

  McComsey, Grace A ^a,b   Lo Re III, V ^c   O'Riordan, M ^a   Walker, U A ^e   Lebrecht, D ^e   Baron, E ^b   Mounzer, K ^d   Frank, I ^c  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d Jonathan Lax Treatment Center   (United States)

^e UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; LACTIC ACID; MITOCHONDRIAL DNA; PYRUVIC ACID; STAVUDINE;

ABDOMINAL PAIN; ADULT; ANOREXIA; ARTICLE; BILIRUBIN BLOOD LEVEL; BODY COMPOSITION; BONE DENSITY; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG DOSE REDUCTION; DRUG EFFECT; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MITOCHONDRION; NAUSEA; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT DURATION; VOMITING; WEIGHT REDUCTION;

ADIPOSE TISSUE; ADULT; ANTI-HIV AGENTS; BODY COMPOSITION; BONE DENSITY; DNA, MITOCHONDRIAL; FEMALE; GENOTYPE; HIV INFECTIONS; HUMANS; LACTIC ACID; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; PYRUVIC ACID; STAVUDINE;

EID: 42549113615     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/529384     Document Type: Article

References (25)

1. Brinkman K, Smeitink JA, Romijn JA, Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 1999; 354:1112-5.
2. Mallal SA, John M, Moore CB, James IR, McKinnon EJ. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS 2000; 14:1309-16.
3. Walker UA, Bickel M, Lutke Volksbeck SI, et al. Evidence of nucleoside analogue reverse transcriptase inhibitor-associated genetic and structural defects of mitochondria in adipose tissue of HIV-infected patients. J Acquir Immune Defic Syndr 2002; 29:117-21.
4. McComsey GA, Walker UA. Mitochondria and HIV lipoatrophy. Mitochondrion 2004; 4:111-8.
5. Nolan D, Hammond E, Martin A, et al. Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy. AIDS 2003; 17:1329-38.
6. McComsey GA, Ward DJ, Hessenthaler SM, et al. Improvement in HAART-associated lipoatrophy in HIV-infected patients switched from stavudine to abacavir or zidovudine: the results of TARHEEL. Clin Infect Dis 2004; 38:263-70.
7. Martin A, Smith D, Carr A, et al. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study. AIDS 2004; 18:1029-36.
8. Moyle GJ, Sabin CA, Cartledge J, et al. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS 2006; 20:2043-50.
9. McComsey GA, Paulsen DM, Lonergan TJ, et al. Improvements in lipoatrophy, mitochondrial DNA content and adipose tissue apoptosis levels after replacement of stavudine with either abacavir or zidovudine. AIDS 2005; 19:15-23.
10. Cherry CL, Lal L, Thompson KA, et al. Increased adipocyte apoptosis in lipoatrophy improves within 48 weeks of switching patients from stavudine to abacavir or zidovudine. J Acquir Immune Defic Syndr 2005; 38:263-7.
11. Hill A, Ruxrungtham K, Hanvanich M, et al. Systematic review of clinical trials evaluating low doses of stavudine as part of antiretroviral treatment. Expert Opin Pharmacother 2007; 8:679-88.
12. Milinkovic A, Martinez E, Lopez S, et al. The impact of reducing stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV-infected patients. Antivir Ther 2007; 12:407-15.
13. AIDS Clinical Trials Group. Available at: http://aactg.s-3.com/members/ download/other/Metabolic/VenousLactateSOP.doc. Accessed 29 February 2008.
14. Setzer B, Schlesier M, Walker UA. Effects of didanosine-related depletion on mtDNA in human T lymphocytes. J Infect Dis 2005; 191:848-55.
15. McComsey G, Bai R, Maa JF, Seekins D, Wong LJ. Extensive investigations of mitochondrial DNA genome in lipoatrophy: beyond mtDNA depletion. J Acquir Immune Defic Syndr 2005; 39:181-8.
16. Cote HC, Brumme ZL, Craib KJ, et al. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med 2002; 346:811-20.
17. Cherry CL, Nolan D, James IR, et al. Tissue specific associations between mitochondrial DNA levels and current treatment status in HIV infected individuals. J Acquir Immune Defic Syndr 2006; 42:435-40.
18. Banas B, Kost BP, Goebel FD. Platelets, a typical source of error in real-time PCR quantification of mitochondrial DNA content in human peripheral blood cells. Eur J Med Res 2004; 9:371-7
19. Nolan D, Hammond E, Martin A, et al. Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy. AIDS 2003; 17:1329-38.
20. Walker UA, Bickel M, Lutke Volksbeck SI, et al. Evidence of nucleoside analogue reverse transcriptase inhibitor-associated genetic and structural defects of mitochondria in adipose tissue of HIV-infected patients. J Acquir Immune Defic Syndr 2002; 29:117-21.
21. Pan G, Yang Z, Ballinger SW, McDonald JM. Pathogenesis of osteopenia/osteoporosis induced by highly active anti-retroviral therapy for AIDS. Ann N Y Acad Sci 2006; 1068:297-308.
22. Carr A, Miller J, Eisman JA, Cooper DA. Osteopenia in HIV-infected men: association with asymptomatic lactic acidemia and lower weight pre-antiretroviral therapy. AIDS 2001; 15:703-9.
23. Bushinsky DA, Krieger NS, Geisser DI, et al. Effects of pH on bone calcium and proton fluxes in vitro. Am J Physiol 1983; 245:F204-9.
24. Lichtenstein KA, Delaney K, Armon C, et al. Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1-infected patients. J Acquir Immune Defic Syndr 2003; 32:48-56.
25. Arenas-Pinto A, International Lactic Acidosis Study Group. International case-control study of lactic acidosis and severe hyperlactatemia in treated HIV-infected adults [abstract 806]. In: Programs and abstracts of the 14th Conference on Retroviruses and Opportunistic Infections (Los Angeles). Alexandria, VA: Foundation for Retroviruses and Human Health, 2007.